Annual Review

2017: a year of integration,
development and growth

Scroll for more

Our
purpose

Our purpose is to provide
efficient and affordable
treatment through an
innovative approach to
health care.

Letter from
the CEO

With the completion of the most successful year after the crisis, we welcome the 85th anniversary of Sopharma AD, this is a reason to strive to become even better in the care for people's health, to affirm the tradition in the production of quality Bulgarian medicines following international recognized standards and technologies and continue to develop as a Group of companies in the healthcare sector.

Read more

Key figures

Sopharma group

For the first time in 2017, Sopharma Group achieved over BGN 1 billion in sales revenue

1017105

(+16%)

BGN '000 revenues

55836

(+24.2%)

BGN '000 operating report

85994

(+16.7%)

BGN '000 ebitda

45772

(-16.6%)

BGN '000 profit

Sopharma AD

2017 was the best year for Sopharma AD after the crisis

205259

(+12.5%)

BGN '000 revenues

41847

(+47.5%)

BGN '000 operating profit

58085

(+32.5%)

BGN '000 ebitda

42239

(+10.1%)

BGN '000 net profit

Key financial indicators
Sopharma group

BGN '000 2017 2016 2015
Revenue 1 017 105 877 085 874 984
EBITDA 85 944 73 656 62 766
Profit from operations 55 836 44 951 36 440
Net profit for the period 45 772 54 902 22 600
EBITDA margin 8% 8% 7%
Operating profit margin 6% 5% 4%
Net debt / EBITDA 3.0x 2.8x 3.6x
Attracted capital / Equity 0.95 0.75

In the past year, a number of companies joined the Group, including Lekovit, Serbia and the pharmacies chain PharmaStore, Bulgaria. There is a process of integration of both structures and the achievement of synergy in all directions of the activity.

REVENUE BREAKDOWN BY SEGMENTS IN 2017

PRODUCT PORTFOLIO BY THERAPEUTIC GROUPS IN 2017

GEOGRAPHICAL SPLIT IN 2017

The companies in Sopharma Group realise that responsible corporate behaviour to stakeholders and especially to investors, partners and users is a prerequisite for sustainable development.

4543

EMPLOYEES in 2016

434

DONATION in 2016

BGN '000

4895

EMPLOYEES in 2017

743

DONATION in 2017

BGN '000

The companies in Sopharma Group realise that responsible corporate behaviour to stakeholders and especially to investors, partners and users is a prerequisite for sustainable development.

22980

COST OF RAW MATERIALS

in 2016

BGN '000

26344

COST OF RAW MATERIALS

in 2017

BGN '000

DIVERSITY - MANAGEMENT BODIES

43.6%

WOMEN

56.4%

MEN

Company
profile
& strategy

Established, trusted brand
with a 85 year track record

Values
& commitments

Our values

2017
at a glance

Sopharma AD
on the stock
exchange

Download
center